For laboratory research use only. Not for human or animal use.

Research compound

Retatrutide (GLP3)

Peptide · Multi-receptor research

Retatrutide is studied for activity at GIP, GLP-1 and glucagon receptors. GLP3 is a catalog alias used for the corresponding Refresh listing; it should not be read as the name of an additional GLP-3 receptor.

Available Products

Mechanism and Research Context

A phase-II trial investigated the triple-receptor agonist in adults with obesity. Its results describe a controlled investigational preparation and a defined study population, rather than the performance of research-catalog material.

Interpreting the Evidence

Keep clinical evidence linked to the manufacturing controls and protocol under which it was generated. A matching name or labeled quantity does not demonstrate equivalence between a commercial research vial and trial material.

Available Research Formats

Browse the Retatrutide (GLP3) listings above for current quantities, pricing and availability. Each product page identifies the format and its labeled contents. Compare the amount per container with the amount per unit where applicable; these are different measurements.

Use the individual listing to review its specifications and available COA link before selecting a material for laboratory work.

Research Goals

Multi-receptor research is the research topic covered in this profile. Topic labels organize the literature; they do not describe an intended treatment or guarantee an experimental result.

Documentation and Handling

Check the identity, composition and storage information supplied with the exact material. Analytical reports describe the sample tested; a source report is not verification of a different lot. Visit the Lab Reports page or contact Refresh Research for documentation questions.

All Refresh Research materials are for laboratory research only, not for human or animal use. See our research-use policy.

References

The publications below provide research context. They are not tests of Refresh Research products.

  1. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial.

Continue exploring

A clearer view of the catalog.

All Compounds